drug · small molecule
METADATE CD
Marketedupdated 3mo agoby $AYTU AYTU BIOPHARMA, INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval746 co-mentions · 201 sources
- drugMETADATE ER462 co-mentions · 206 sources
- drugRITALIN LA428 co-mentions · 206 sources
- drugQuillivant XR406 co-mentions · 206 sources
- drugMethylin404 co-mentions · 206 sources
- drugMETHYLIN ER404 co-mentions · 206 sources
- drugmethylphenidate hydrochloride ER388 co-mentions · 206 sources
- drugRelexxii384 co-mentions · 206 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 11 investigational indications.
targets
Sodium-dependent dopamine transporterSodium-dependent noradrenaline transporter
all catalysts(25)
approval · 25
Apr 3, 2001
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Apr 9, 2002
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Sep 18, 2002
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Nov 6, 2002
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Nov 6, 2002
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
May 27, 2003
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Jun 19, 2003
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Sep 22, 2003
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Feb 19, 2006
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Aug 10, 2006
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
May 4, 2007
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Aug 26, 2008
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Apr 16, 2009
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Oct 18, 2010
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
May 6, 2013
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
May 6, 2013
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Jun 4, 2013
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Dec 13, 2013
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Apr 17, 2015
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Jun 15, 2015
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Jan 4, 2017
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Jun 25, 2021
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Apr 22, 2022
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Oct 13, 2023
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Sep 23, 2025
approval
$AYTU2.2300-0.89%
METADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
METADATE CD
→
Trials studying METADATE CD
- phase3Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD
- phase1Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions
- phase1Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions
- phase4A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
News(2)
- Recon: FDA grants Concerta generic withdrawal hearing; Ivonescimab wins first-line NSCLC nod in ChinaWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 5d ago
- FDA scientists question Capricor data; Legend CEO steps downCapricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…biopharma_dive · 21d ago
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that